Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glycogen synthase kinase 3 (GSK‐3) has been regarded as a potential therapeutic target for multiple human cancers. We previously reported that suppression of GSK‐3 activity with lithium chloride (LiCl) or small chemical inhibitors impaired cellular DNA synthesis and reduced cell proliferation in prostate cancer cells. Therefore, in this study, we extended this in vitro findings to in vivo settings in order to establish a proof of concept that inhibition of GSK‐3 activity is feasible in suppressing tumor growth of prostate cancer in vivo. METHODS: In this study, we used three GSK‐3 inhibitors, LiCl, TDZD‐8, and L803‐mts, which are structurally unrelated and non‐ATP competitive. Human prostate cancer cell lines PC‐3 and C4‐2 were used for nude mouse xenograft models. The autochthonous transgenic prostate cancer TRAMP mice were used for testing GSK‐3 inhibitor's effect on tumor development. Anti‐Ki‐67 and BrdU immunohistochemistry was used to determine cell proliferation. The pE2F‐TA‐LUC (E2F‐LUC) luciferase reporter assay and gene specific small interferencing RNA technique were used to examine C/EBP involvement in GSK‐3 inhibitor‐induced E2F‐1 suppression. RESULTS: Using mouse xenograft models, we demonstrated that LiCl and TDZD‐8 significantly suppressed tumor development and growth of subcutaneous xenografts derived from human prostate cancer cells. Similarly, in the TRAMP mice, TDZD‐8 and L803‐mts reduced the incidence and tumor burden in the prostate lobes. Consistent with our previous in vitro findings, GSK‐3 inhibitors significantly reduced BrdU incorporation and Ki67‐positive cells in xenograft tumors and mouse cancerous prostates compared to the control. Further analysis revealed that following GSK‐3 inhibition, C/EBPα, a negative cell cycle regulator, was remarkably accumulated in xenograft tumors or in cultured prostate cancer cells. Meanwhile, knocking down C/EBPα expression abolished GSK‐3 inhibition‐induced suppression of E2F1 transactivation, suggesting that C/EBPα accumulation is involved in GSK‐3 inhibition‐induced anti‐tumor effect. CONCLUSION: Taken together, these results suggest that GSK‐3 inhibition has the potential as a therapeutic strategy for prostate cancer intervention, although further pre‐clinical and clinical testing are desirable. Prostate 71:835–845, 2011. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 1×
“As a clinical drug for mental disease, lithium ion is a non-ATP competitive GSK-3 inhibitor [22,23].”
BackgroundNoble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 1×
“This lithium dose level was based on a previous report where a biological effect was observed in rat models [31], and is more than 100-fold lower that a therapeutic dose for mental diseases inmouse [32] or human [33].”
Background
Cited by
PI3K/Akt signaling in osteosarcoma
Zhang, J., Yu, X.-H., Yan, Y.-G., Wang, C., & Wang, W.-J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.041 · Cited by 327
Wei, J., Wang, J., Zhang, J., Yang, J., Wang, G., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114301 · Cited by 42
Self-citationGSK3β inhibition and canonical Wnt signaling in mice hearts after myocardial ischemic damage
Badimon, L., Casaní, L., Camino-Lopez, S., Juan-Babot, O., & Borrell-Pages, M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218098 · Cited by 32
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228709 · Cited by 25
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Borden, B. A., Baca, Y., Xiu, J., Tavora, F., Winer, I., Weinberg, B. A., Vanderwalde, A. M., Darabi, S., Korn, W. M., Mazar, A. P., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0497 · Cited by 15
Metadata
- Authors
- Zhu, Q., Yang, J., Han, S., Liu, J., Holzbeierlein, J., Thrasher, J. B., & Li, B.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2010-10-28
- Volume
- 71
- Issue
- 8
- Pages
- 835-845
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W1994994301
- Cited by
- 98
- References
- 2
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.